Valeant Pharmaceuticals was on the verge of its biggest deal yet last week. Until merger talks with generics giant Actavis fell apart, that is.
A union fund is suing Warner Chilcott, Watson Laboratories and Lupin, claiming that their Loestrin 24 Fe patent settlements amounted to unfair market-sharing deals that cost payers money. Warner's key patent on the formula was weak, the fund claims, and the generics makers only backed away because Warner paid them to.
Lipitor as a loss leader? That's the approach Wegmans' pharmacies are taking. As the Philadelphia Inquirer reports, the grocery store chain offers generic versions of Lipitor for free, as a way to bring in new pharmacy customers. And the promotion must be successful--Wegmans just extended it through the end of this year.
Actavis, the former Watson Pharmaceuticals, said its fourth-quarter earnings paled by comparison to a year ago when it first released an official generic of Lipitor.
A federal appeals court decided in favor of Cephalon in a dispute with Actavis ($ACT) over an oral mucosal drug delivery patent.
Watson Pharmaceuticals is no more. The generic drug company has officially taken the name of its most recent acquisition target, Actavis, thinking it has better brand recognition in the markets where it intends to expand.
Stada CEO Hartmut Retzlaff has been elusive about what the future holds for the German generics maker, which has often popped up at the center of buyout rumors. But Stada's Markus Metzger acknowledged that if someone makes a significant offer, the board would give a good look.
With generous tax laws, incentives and a location ideal for servicing Southeast Asia, Malaysia is drawing new plants from manufacturers looking to expand in those markets.
Now that Actavis CEO Claudio Albrecht is all but out of a job, rumor has it that he's trying to put together a deal for German generics maker Stada. Albrecht, whose company will be taken over by Watson Pharmaceuticals ($WPI) in the new year, is reportedly scouting for Stada investors willing to sell.
Mergers and acquisitions by drug companies were off big time this year, down by 35% overall. Much of what is getting invested is targeted at emerging markets, with China not surprisingly leading the list.